JS007 / Shanghai Junshi Bioscience - LARVOL DELTA

JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma: updated results from a Phase Ⅱ study (ESMO 2026) - No abstract available

Bispecific • Clinical • Metastases • Hepatocellular Cancer • Oncology • Solid Tumor

JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer (clinicaltrials.gov) - P3 | N=560 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P3 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy. (PubMed, Int Immunopharmacol) - "Therapeutic antibodies targeting CTLA-4, including the FDA-approved agents ipilimumab and tremelimumab, achieve checkpoint blockade through steric occlusion of the B7-binding interface, inhibition of transendocytosis, and Fc-mediated regulatory T-cell depletion...Other antibodies, including JS007, have entered clinical evaluation, while structurally characterized agents such as mipi.4 and KN044 provide preclinical and translational insights. Emerging engineering strategies, Fc-optimized variants, tumor-activated prodrug formats, bispecific antibodies, and alternative scaffolds such as nanobodies and DARPins are now translating these structural insights into next-generation therapeutics with improved selectivity and reduced immune-related adverse events. By connecting atomic-level receptor recognition to clinical outcome, this review provides a mechanistic foundation for the rational design of next-generation CTLA-4 therapeutics with improved efficacy and reduced..."

Journal • Review • Immunology • Oncology

JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study (AACR 2026) - P2 | "Conclusion The combination of JS207 and JS007 demonstrated promising efficacy with an acceptable safety profile as first line treatment of advanced HCC. The randomized expansion phase of this study is ongoing."

Bispecific • Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

#CT159: Preliminary results from a phase 2 study evaluating JS207 in combination with JS007 as first-line treatment for advanced hepatocellular carcinoma (HCC) (GlobeNewswire) - "Shanghai Junshi Biosciences...announced that early clinical results from four studies across its innovative pipeline were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting....As of March 20, 2026, a total of 26 patients had received JS207 plus JS007, including 7 patients in the safety run-in period and 19 patients in the randomized expansion phase. Among the 22 evaluable patients, the objective response rate (ORR) reached 45.5% while the disease control rate (DCR) was 86.4%. JS207 plus JS007 was well-tolerated, with no dose-limiting toxicities (DLT) observed during the safety run-in period."

P2 data • Hepatocellular Cancer

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors. (PubMed, Exp Hematol Oncol) - P1 | "JS007 preliminarily demonstrates good tolerance and encouraging antitumor activity in patients with previously treated advanced solid tumors."

Journal • Metastases • P1 data • Preclinical • Oncology • Solid Tumor

FD-IMPACT: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (clinicaltrials.gov) - P1/2 | N=117 | Not yet recruiting | Sponsor: Fudan University

New P1/2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors (ESMO 2023) - P1 | "Conclusions JS007 is well-tolerated with preliminary promising efficacy in heavily pretreated pts. The dose expansion phase is still ongoing, and the combination of JS007 with the anti-PD-1 antibody toripalimab is planned."

Clinical • Metastases • P1 data • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • CTLA4

Clinical Study of JS007 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Shanghai Junshi Bioscience Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

Clinical Study of JS007 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor

Junshi Bio’s CTLA-4 mAb JS007 gets first trial nod in China (GBI Health) - "Shanghai-based biotech Junshi Biosciences (HKEX:1877; SSE:688180) announced clinical trial approval from the National Medical Products Administration (NMPA) for its JS007. The targeted indication is advanced malignant tumors."

Non-US regulatory • Oncology

Junshi Bio’s CTLA-4 mAb JS007 under trial review in China (GBI Health) - "Shanghai-based biotech Junshi Biosciences (HKEX:1877; SSE:688180) announced that the clinical approval filing for its JS007 has been accepted for review by the National Medical Products Administration. JS007, an in-house developed humanized CTLA-4 monoclonal antibody, is under development to treat advanced malignant tumors."

Non-US regulatory • Oncology